IDXX - IDEXX: A Closer Look At One Of The Market's Best Compounders

2024-02-07 07:58:28 ET

Summary

• IDEXX Laboratories reported strong financial performance in 4Q23, with an 8% increase in organic revenues.
• The company experienced growth in its Companion Animal Group segment, particularly in diagnostic recurring revenue.
• IDEXX's outlook includes projected revenue growth of 7-10% and continued investment in innovation and technology for future growth.

Introduction

On November 2, I wrote an article titled "IDEXX: A Realistic Path To 12-14% Annual Returns."

The article, which covered IDEXX Laboratories (IDXX) , discussed one of the most aggressive compounders in the healthcare space, a stock that has returned 21% per year since 2004!...

For further details see: